Adial pharmaceuticals regains compliance with nasdaq listing requirements

Charlottesville, va., aug. 23, 2023 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil; adilw) (“adial” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from nasdaq on august 21, 2023 that the company has regained compliance with the minimum bid price requirement set forth in nasdaq listing rule 5550(a)(2). nasdaq determined that for the last 10 consecutive business days, from august 7 through august 18, 2023, the closing bid price of the company's common stock has been at $1.00 per share or greater.
ADIL Ratings Summary
ADIL Quant Ranking